Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

New treatments for diabetic nephropathy?

July 18th 2014

Renal failure secondary to diabetes is one of the three microvascular diabetic complications. In many ways, it is the most feared since there is not only the inevitable outcome of end-stage renal failure (ESRF) requiring dialysis or transplantation, but also a greatly increased risk of both small vessel and large vessel complications, especially cardiovascular disease (CVD).

The good news is that rates of development of ESRF in people with type 1 diabetes appear to be declining. We presume that this reflects better (albeit inadequate) levels of glyceamic control along with attention to blood pressure and lipids. The bad news is that diabetes accounts for the majority of patients with ESRF in the United States, due to the epidemic of type 2 diabetes (T2DM).

Current management of diabetic nephropathy (DN) is to reduce progression from microalbuminuria to persistent proteinuria and ultimately declining renal function by reduction of blood pressure (BP) and hyperglycaemia. The primacy of ACE-inhibitors (and ARBs) has, in my view, been over-emphasised and the decline in kidney function is only delayed rather than halted. New treatments are urgently needed.

Trials of bardoxalone, a drug which reduces oxidative stress and inflammation, were promising but have ultimately been halted due to adverse events. Now, four other randomized controlled trials (RCTs) are on-going to assess new agents.

The first, and possibly least-inspiring, is a trial of allopurinol (the PERL study), set up on the basis that elevated uric acid levels are seen in patients with DN. Two other studies are assessing the impact on DN of drugs which are already licensed for the treatment of T2DM. CARMELINA is a CV safety study of linagliptin (vs. placebo) which has secondary renal end-points and has been set up on the basis that DPP-4 is highly expressed in renal tissue. CREDENCE is a five-year study of the sodium-glucose co-transporter inhibitor, canagliflozin, which has primary renal end-points and is examining the hypothesis that the reduction in both GFR and albumin excretion seen with the drug is renoprotective.

Finally, the SONAR study examines the impact of atrasentan, a member of a new class of therapeutic agents (in diabetes, at least), known as endothelin receptor inhibitors. A small pilot study (RADAR) published earlier this year has shown promising impacts on albumin excretion rate, BP and triglycerides, leading to the current RCT in over 4,000 patients. Watch this space….

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskAstraZenecaSanofi Diabetes

Silver Sponsors

AmgenWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership